The interaction of acute lymphoblastic leukemia (ALL) blasts with bone marrow (BM) stromal cells (BMSCs) has a positive impact on ALL resistance to chemotherapy. We investigated the modulation of a series of putative asparaginase-resistance/ sensitivity genes in B-precursor ALL cells upon coculture with BMSCs. Coculture with stromal cells resulted in increased insulinlike growth factor (IGF)-binding protein 7 (IGFBP7) expression by ALL cells. Assays with IGFBP7 knockdown ALL and stromal cell lines, or with addition of recombinant rIGFBP7 (rIGFBP7) to the culture medium, showed that IGFBP7 acts as a positive regulator of ALL and stromal cells growth, and significantly enhances in-vitro resistance of ALL to asparaginase. In these assays, IGFBP7 function occurred mainly in an insulin-and stromal-dependent manner. ALL cells were found to contribute substantially to extracellular IGFBP7 levels in the conditioned coculture medium. Diagnostic BM plasma from children with ALL had higher levels of IGFBP7 than controls. IGFBP7, in an insulin/IGF-dependent manner, enhanced asparagine synthetase expression and asparagine secretion by BMSCs, thus providing a stromal-dependent mechanism by which IGFBP7 protects ALL cells against asparaginase in this coculture system. Importantly, higher IGFBP7 mRNA levels were associated with lower leukemia-free survival (Cox regression model, P ¼ 0.003) in precursor B-cell Ph(À) ALL patients (n ¼ 147) treated with a contemporary polychemotherapy protocol.
INTRODUCTION
Substantial successes have been achieved in the treatment of children with acute lymphoblastic leukemia (ALL). However, relapse still occurs in around 20% of patients. A large number of studies have shown that the persistence of blasts in the peripheral blood or bone marrow (BM) after the first weeks of treatment is highly predictive of relapse. 1 An early response to therapy reflects both the intrinsic resistance of leukemic cells to antileukemic agents 2, 3 and host factors related to drug pharmacodynamics. 4 Several genetic abnormalities are known to contribute to the development of ALL and in some cases, such as the t(9;22) translocation or in infants with MLL gene rearrangements, there is also a higher in-vitro drug-resistance phenotype 5, 6 and rate of treatment failure. 7, 8 Conversely, there are also genetic abnormalities, like the t(12;21) translocation, which have been reported to be associated with a more favorable drug uptake and chemosensitivity. 9, 10 Although it is likely that resistance to chemotherapy is mainly determined by the intrinsic genetic characteristics of leukemic cells, several mechanisms that confer drug resistance in ALL cells in the BM may be also modulated by leukemia-host interactions. Several authors have shown that the interaction of ALL blasts with BM stromal cells (BMSCs) has a positive impact on leukemia cell survival 11 --16 and enhances ALL resistance to chemotherapy. 17 --22 Very little is known about the molecular mechanisms that contribute to stromal-induced ALL chemoresistance. Interactions with stromal vascular cell adhesion molecule 1 cell adhesion molecules render VLA-4 þ leukemic cell lines resistant to Ara-C and VP-16 (etoposide). 17 Stromal cells protect ALL cell lines from the pro-apoptotic effect of chemotherapy by inducing the activation of the PI3K 21 and AKT 21 survival pathways and by downregulating caspase 3 activity. 18 In addition, vascular endothelial growth factor produced by stromal cells stimulates Bcl-2 phosphorylation and resistance of ALL cell lines to different chemotherapeutic agents. 23 More recently, Iwamoto et al. 22 showed that stromal cells (BM mesenchymal cells) synthesize and secrete asparagine in sufficient amounts to protect ALL cells, both cell lines and primary cells, from asparaginase cytotoxicity. Microarray analysis in combination with in-vitro drug sensitivity assays of diagnostic ALL samples were used to identify different sets of genes with expression patterns linked to sensitivity or resistance to prednisolone, vincristine, asparaginase and daunorubicin. 24 We reasoned that some of these genes could also be involved in the stromal-induced ALL chemoresistance. In this manuscript, we investigated the stromal modulation of a series of putative asparaginase-resistance/sensitivity genes in primary B-lineage ALL cells. Coculture with stromal cells induced the upregulation of insulin-like growth factor (IGF)-binding protein 7 (IGFBP7) in ALL cells, a gene that has been previously associated with asparaginase-resistant ALL. 24 A series of experiments with IGFBP7 knockdown ALL and stromal cell lines and with addition of recombinant IGFBP7 (rIGFBP7) to the culture medium were carried out to investigate the possible contribution of IGFBP7 on ALL resistance to asparaginase. Evidence was found that rIGFBP7:insulin (or rIGFBP7:IGF-1 or :IGF-2) stimulates the expression of asparagine synthetase (ASNS) and the secretion of asparagine by BMSCs, providing one possible mechanism by which IGFBP7 protect ALL cells against asparaginase in this coculture system.
MATERIALS AND METHODS

Leukemia, BMSCs and mesenchymal stem cells
Primary leukemia samples used for in-vitro assays were cryopreserved BM mononuclear cells obtained from patients with a newly diagnosed B-lineage ALL and with a diploid karyotype and/or DNA index of 1±0.1 (Supplementary Table 1 ). Samples were used if thawed vials yielded 490% of viable cells, as judged by Trypan blue staining. The prognostic impact of IGFBP7 transcript levels was evaluated in post-ficoll BM mononucleated cells, stored at À70 1C in guanidine solution, from 181 ALL patients that entered treatment from January 2002 to the end of July 2007 at Centro Infantil Boldrini. Patients were treated according to the Brazilian GBTLI-99 Childhood ALL Treatment protocol. 25 Normal BM samples were obtained from healthy transplant donors included as controls. Diagnostic BM aspirate smears were used to estimate the leukemic blasts concentration in BM: three different areas of 164 Â 206 mm were photographed at the microscope, nucleated cells were counted, using the NIS-Elements AR software (Nikon, Tokyo, Japan), and corrected according to blasts percentage. BM blast percentages ranged from 40 to 98% (median 90%, interquartile 75 --95%). Median blast cell concentrations in BM were 138.3 (interquartile range 62.64--274.9). The study was approved by the Research Ethics Committees from both Centro Infantil Boldrini and State University of Campinas.
BMSCs were obtained from donor BM mononucleated cells as described. 12 Cells at passages 1 --3 were used in the experiments. Coculture experiments with ALL cell lines were performed with the use of hTERT (telomerase reverse transcriptase) immortalized mesenchymal stem cells (MSCs), 26 kindly provided by Dr Dario Campana (St Jude Children's Research Hospital, Memphis, TN, USA). The leukemia cell lines 697, RS4;11 and REH were kindly provided by Dr Sheila A Shurtleff (St Jude Children's Research Hospital) and Nalm6 by Dr Angelo Cardoso (Dana-Farber Cancer Institute, Boston, MA, USA). MSCs and ALL cell lines were maintained in RPMI-1640 containing 10% fetal calf serum (RPMI-10%).
shRNA knockdown of IGFBP7 in RS4;11, REH, 697, and MSCs cells IGFBP7 expression was downregulated by stable transfection of ALL cell lines and MSCs with the pLKO.1 MISSION shRNA lentiviral vector NM_001553.1-959s1c1 (Sigma-Aldrich, St Louis, MO, USA). The IGFBP7 shRNA sequence corresponds to nucleotides 959 --979 (NM_001553.1). As negative control, cells were transduced with the MISSION Non-Target shRNA Control Vector (Sigma-Aldrich). Vesicular stomatitis virus-pseudotyped lentiviral vectors were produced by transient transfection of the MISSION vector in conjunction with pMDLg/pRRE, pRSV-Rev and pMD2.G vectors, into 293T cells. Conditioned medium containing lentivirus were harvested and used for infection of cells. After 72 h, infected RS4;11, REH, 697 and MSCs cells were selected with 1.5, 2.5, 1.5 or 3 mg/ml puromycin, respectively, during 20 days, and bulk cells were used for the experiments. For experiments, cells were cultured without puromycin for 1 week.
Coculture and gene expression analysis
BMSCs were grown to subconfluence in 6-well plates. Immediately before initiating the experiments, the medium was removed and the cells were washed twice with 2 ml of phosphate-buffered saline (PBS) and once with AIM-V serum-free culture medium (Invitrogen, Carlsbad, CA, USA). Cryopreserved primary ALL cells were thawed, washed in AIM-V and 10 Â 10 6 cells were seeded onto BM stromal layers in 5 ml AIM-V medium, and incubated at 37 1C and 5% CO 2 . In the case of cell lines, ALL cells were starved overnight in RPMI-1640 serum-free medium, pelleted and 5 Â 10 6 cells/well were seeded onto subconfluent MSCs in serum-free RPMI-1640. At predetermined times of coculture, ALL cells were collected by pipetting and scraping the bottoms of wells, and washed twice with PBS. Collected ALL cells were used for RNA extraction. For certain experiments, tightly adherent ALL cells were recovered from BM stromal layers by the addition of a solution containing 0.25% trypsin and incubation at room temperature under continued microscopy inspection in order to avoid detachment of BMSCs. To address the possible influence of cell viability on gene expression results, matched primary ALL samples (3 Â 10 5 cells) were seeded in triplicate onto confluent BM stromal layers in 96-well plates in 200 ml of coculture medium and then collected at various time points (6 h, 1 day, 2 days and 3 days) for the analysis of number of viable cells by trypan blue dye exclusion.
One microgram of total RNA was used for cDNA synthesis with 100 ng of random hexamers and the ImProm II reverse transcriptase (Promega, Madison, WI, USA). cDNA quality was evaluated by a multicontrol PCR assay. 27 The quantitative assessment of gene transcripts was made by realtime PCR (RQ-PCR) on an ABI PRISM 7300 (Applied Biosystems, Carlsbad, CA, USA) using the SYBR green method. Standard curves were prepared by serial dilutions of PCR products from 10 6 to 10 3 molecules. Absolute gene transcript values were normalized with respect to the number of ABL transcripts. 28 Primers and the PCR protocol are presented in Supplementary Methods.
Stromal cell treatment with IGFBP7 and/or its ligands
BMSCs were cultured to confluence in appropriate culture medium (see above) and then washed and incubated overnight in AIM-V. In the following day, different combinations of rIGFBP7 (R&D Systems, Minneapolis, MN, USA) at 100 ng/ml, IGF1 (R&D Systems) at 200 ng/ml, IGF2 (R&D Systems) at 200 ng/ml and insulin (Novolin N, Novo Nordisk, Bagsvaerd, Denmark) at 500 ng/ml were added. After 6 h of incubation, medium was removed and cells were lysed by TRIZOL addition to the plates. Treatments were done in triplicate. Cell lysates were used for RNA extraction and gene expression analysis.
Measurement of amino-acid concentrations in culture media
BMSCs were cultured to confluence, washed and incubated for 24 or 48 h in serum-free, asparagine-free MEM medium (Cultilab, Campinas, Brazil) supplemented with different combinations of rIGFBP7, IGF1, IGF2 and insulin (same concentrations as above). After the incubation period, the culture media were recovered and detached cells were pelleted by centrifugation. Amino acids were separated and analyzed by reverse-phase high-performance liquid chromatography as their o-phthalaldehyde derivatives, as previously described. 29 Flow cytometry analysis of intracellular IGFBP7 expression Primary ALL cells (1 Â 10 6 cells) or starving ALL cell lines (0.1 Â 10 6 cells) were cultured with and without BMSCs or MSCs in 24-well plates in 1 ml of AIM-V or RPMI-1640 serum-free medium, respectively, as described above. After 24 h, ALL cells were recovered, washed with PBS/0.5% bovine serum albumin (PBS/BSA), blocked in PBS containing 2% human AB serum, labeled with CD19-FITC (BD Pharmingen, San Diego, CA, USA) and fixed in 0.5% paraformaldehyde. Cells were then washed, permeabilized for 10 min with PBS/BSA/0.5% saponin and labeled with goat polyclonal antibody anti-IGFBP7 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Cells labeled with the primary antibody plus blocking peptide were used as control. After washing with PBS/BSA/saponin, cells were labeled with the secondary donkey anti-goat IgG F(ab')-APC (Santa Cruz Biotechnology), washed and fixed in paraformaldehyde. Cells were analyzed with a FACSCanto flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) using the BDFACSDiva Software (Becton Dickinson). A 'gate' was designed around the area of the light-scatter dot plot (forward scatter vs side scatter) in which the majority of live leukemic cells were found, excluding apoptotic cells, cell debris and aggregates. Apoptotic cells accumulate as an additional population, of decreased volume and increased density, in the forward scatter vs side scatter plots, 30 and therefore were easily excluded from the count. Only CD19( þ ) cells were analyzed with respect to intracellular IGFBP7 labeling. Cells labeled with primary antibody plus blocking peptide (Santa Cruz Biotechnology) were used as negative control.
ELISA
IGFBP7 levels in culture media and patients' BM plasma were measured using sandwich ELISA, as described elsewhere. 31 The group of patient's BM plasma samples had only a partial overlap (n ¼ 42) with BM mononuclear cells used for gene expression analysis. Stable MSC cell lines expressing sh.IGFBP7 or sh.Scrambled were grown to 50% confluence (3000 cells) in 96-well plates in RPMI-10%. Immediately before initiating the experiments, the medium was removed and the cells were washed twice with serumfree RPMI-1640. Stable ALL cell lines expressing sh.IGFBP7 or sh.Scramble were grown in RPMI-10%, washed in serum-free RPMI-1640 and 1 Â 10 5 or 5 Â 10 5 cells were seeded onto the subconfluent MSC layers in 100 ml serum-free RPMI-1640 medium, and incubated at 37 1C and 5% CO 2 . After 24 h, the culture media were recovered and centrifuged, and the supernatant was used for ELISAs.
Cell survival/proliferation assays Primary B-precursor ALL cells (2 Â 10 5 cells) were seeded onto subconfluent BMSC or MSC layers, or as described above, in 96-well plates in 100 ml of AIM-V medium supplemented with different combinations of asparaginase (0.9 IU/ml), rIGFBP7 (100 ng/ml) and insulin (500 ng/ml). Similar experiments were performed with ALL cell lines (5 Â 10 4 cells/ well), cultured with and without MSCs in RPMI-10%. After incubation for 48 h, cells were harvested by pipetting and scraping the bottoms of wells, pelleted by centrifugation, resuspended in PBS/BSA and incubated on ice for 30 min with the CD19-FITC antibody (BD Pharmingen). After one wash in PBS, cells were resuspended in 300 ml PBS, 10 ml of CountBright Absolute Counting Beads (Molecular Probes, Eugene, OR, USA) was added and samples were analyzed by flow cytometer using a forward scatter vs side scatter 'gate' for viable cells, as described above. 30 The number of viable CD19( þ ) cells per 3000 beads events was recorded. All treatments were done in triplicate. Similar experiments were performed but recovered cells were labeled with Annexin V and propidium iodide. Briefly, cells were resuspended in the appropriate binding buffer, stained with Annexin V Alexa Fluor 488 conjugated (Life Technologies, Carlsbad, CA, USA) and propidium iodide at room temperature for 15 min, and subsequently analyzed by flow cytometry, and the absolute number of Annexin-negative cells per 3000 beads events was recorded.
Statistical analysis
IGFBP7 mRNA expression values had a positively skewed distribution and were transformed into logarithmic values. The association of IGFBP7 expression levels (natural logarithmic values) with clinical and biological features was determined by the Mann --Whitney test. When necessary, continuous variables were considered using previously defined discrete categories. Survival analysis included 153 precursor B-cell ALL patients, negative for the BCR-ABL translocation. Of these, six patients died during induction due to sepsis (n ¼ 4) or hemorrhagic disorders (n ¼ 2) and were excluded from the analysis. Leukemia-free survival (LFS) denotes period of time from remission date to any relapse (n ¼ 7). Failure to enter remission due to refractory disease (n ¼ 3) was considered an event at zero time. Patients who died in remission (n ¼ 7) were censored on the day of death. Patients still alive and without any relapse were censored at last follow-up. A patient who had BM transplantation in first remission was censored at the day of transplantation. The median follow-up period for patients who did not have an event was 3.9 years (interquartile range 2.65 --5.04 years). The Cox regression model was used to test the prognostic influence of IGFBP7 expression as a continuous variable as well as to adjust for the effect of other variables (gender, age, white blood cell count at diagnosis, presence of the TEL-AML1 translocation, CD10 immunophenotype, BM status at day 28 and risk group). Backward elimination procedure was employed. The Wald's test was used to determine whether variables should be dropped from the multivariate model. Alpha errors of P ¼ 0.05 and P ¼ 0.1 were tolerated in univariate analyses and the multivariate model, respectively. The SPSS 17.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA) softwares were used throughout.
RESULTS
The asparaginase-resistance/sensitivity genes analyzed in this study were selected from the work of Holleman et al. 24 according to the reported ratios of the median expression in drug-resistant vs drug-sensitive B-lineage ALL cells (R/S ratio). Five genes were selected, including two sensitivity genes (R/S ratio o1.0), GPR56 and MAN1A1, and three resistance genes (R/S ratio 41.0), SCGF, IGFBP7 and GATA3. Gene expression was analyzed in a series of 12 --17 clinical samples of pediatric B-lineage ALL before and after 6 h of culture on allogeneic BM stromal layers. As shown in Figure 1a , both the GPR56 and MAN1A1 sensitivity genes were downregulated in ALL cells after 6 h of culture on the stromal layer. On the other hand, two (IGFBP7 and GATA3) of the three drug-resistance genes were upregulated after culture with stromal cells. After 3 days of culture on BM stromal layers, half (9 out of 17) of the ALL samples demonstrated some degree of proliferation. In contrast, in 3/17 and 5/17 of cases, the number of viable ALL cells remained constant or decreased, respectively, as judged by trypan blue exclusion (data not shown). No association could be found between ALL survival/proliferation in culture and the expression of the five drug-sensitivity/resistance genes.
IGFBP7/mac25/IGFBP-rP1 was selected for subsequent studies based upon its fold upregulation, its soluble or extracellular activity and the availability of rIGFBP7 protein. During the course of the experiments, we noticed that substantial numbers of primary ALL cells remained tightly associated with the BM stromal layer after the washing procedure. Since IGFBP7 was reported to display cell adhesion activities, 32 --34 we speculated whether its expression could be linked to the different adhesion phenotypes of ALL cells. As shown in Figure 1b , no statistically significant differences could be found between the expression of IGFBP7 and the adhesion phenotypes of ALL cells, even though a small trend was seen toward higher expression in highly adherent cells. Importantly, simply culturing ALL cells without the stromal layer resulted in IGFBP7 downregulation in comparison with the levels found at time zero. Consistent with RQ-PCR results, the intracellular expression of IGFBP7 antigen in ALL cells was significantly upregulated after culture on BM stromal layers, as indicated by the median fluorescence intensity of labeled cells (Figure 1c) .
To test the observations made with primary ALL cells, experiments were performed with ALL cell lines, which survive equally well with and without BM stromal layers. Upregulation of IGFBP7 was seen in the four different ALL cell lines tested (Nalm6, REH, RS4;11 and 697), upon coculture with hTERT-MSCs (MSCs), 26 a BM-derived stromal cell line, compared with medium alone (Supplementary Figure 1) .
Autocrine effect of IGFBP7 on ALL cells IGFBP7 was first described as an enhancer of the mitogenic activities of IGFs and insulin. 35 Since ALL cells respond to IGFs and/ or insulin stimulation, 36 --41 the leukemia-derived IGFBP7 could work as an autocrine factor. To investigate this possibility, the ALL cell lines REH, RS4;11 and 697 were stably transduced with lentiviral particles carrying shRNA constructs directed against IGFBP7 (sh.IGFBP7) or a non-coding random sequence (sh.scrambled). Expression of IGFBP7 was decreased to equivalent levels in shRNA-IGFBP7-transduced REH and RS4;11 cells (Figure 2a) . Downregulation of IGFBP7 markedly reduced the rate of growth of REH and 697 cells in comparison with shRNA scrambled-transduced cells, but had no apparent effect on RS4;11 cells (Figure 2b ). ALL is a heterogeneous disease. Results suggest that the different cell lines may have evolved different growth factor requirements, and that IGFBP7 may potentially exert an autocrine effect on ALL cells.
Paracrine effect of ALL-derived IGFBP7 on BM stromal cells Since many different cells respond to IGFs and/or insulin, the leukemiaderived IGFBP7 could act in a paracrine manner on BM stromal cells. As shown in Figure 2c , addition of rIGFBP7 to the culture medium had a mitogenic effect on MSCs. However, in the course of this study we found out that BM stromal cells also express the IGFBP7 gene (Figure 2a) . To investigate whether the leukemia-derived IGFBP7 have any impact on BM stromal cells, MSCs were stably transfected with shRNA constructs against IGFBP7 or a random non-coding sequence. As expected, IGFBP7 downregulation had a detrimental effect on the rate of growth of MSCs (Figure 2c) . Addition of rIGFBP7 to the culture medium rescued the growth rate of IGFBP7 knockdown MSCs back to normal. Notably, addition of conditioned culture media (1:1) obtained from REH or RS4;11 cells stably transduced with the shRNA scrambled vector fully rescue the growth rate of IGFBP7 knockdown MSCs, whereas a markedly reduced effect was seen with conditioned culture media of sh.IGFBP7-transduced REH or RS4;11 ( Figure 2c ). These results suggest that the leukemia-derived IGFBP7 may potentially exert a paracrine effect on BM stromal cells.
IGFBP7 enhances the asparaginase resistance of ALL cells, mainly in a stromal-dependent manner To determine whether IGFBP7 could enhance ALL resistance to asparaginase, we cultured different ALL cell lines in medium supplemented with different combinations of asparaginase (Nalm6---1.0 IU/ml; REH---2.0 IU/ml; 697---3.0 IU/ml and RS4;11---0.001 IU/ml), rIGFBP7 (100 ng/ml) and/or insulin (500 ng/ml). Cells were cultured either alone or onto MSC layers. Importantly, asparaginase was not cytotoxic to BM stromal cells at the dose used (Supplementary Figure 2A) . Cell survival/proliferation was evaluated by FACS (Supplementary Figure 3) . 'Gates' were designed around the area of the light-scatter dot plot (forward scatter vs side scatter) in which the majority of live leukemic cells were found. 30 Absolute counting of viable CD19( þ ) cells was obtained by using an internal microsphere counting standard. Even though addition of rIGFBP7 plus insulin promoted a slight increase in asparaginase resistance in the absence of MSCs, the effect of IGFBP7:insulin was higher in the presence of MSCs (Figure 3a) .
To determine the contribution of the endogenously produced IGFBP7 on ALL resistance to asparaginase, experiments were performed with the IGFBP7 knockdown cell lines. The number of viable cells was measured by an Annexin V-based assay in conjunction with the microsphere counting standard. As shown in Figure 3b and Supplementary Figure 4 , IGFBP7 downregulation in REH, RS4;11 and 697 cells, and to a lesser extent in the MSCs stromal cells, resulted in decreased resistance of cocultured ALL cells against asparaginase. Notably, resistance could be restored back to a level seen with control cells by the addition of rIGFBP7 to the coculture medium.
These findings were confirmed by performing similar experiments with primary B-precursor ALL cells cultured on MSCs. As shown in Figure 4 and Supplementary Figure 5 , addition of rIGFBP7 plus insulin to the culture medium caused a significant increase in ALL survival against asparaginase in five out of six samples analyzed. Compatible results were obtained with coculture assays on primary BMSCs (Supplementary Figure 6) and when rIGFBP7 was used in conjunction with IGF1 or IGF2 (data not shown). Increased IGFBP7 in the malignant BM microenvironment Since both ALL and stromal cells secrete IGFBP7, both cell types would likely contribute to IGFBP7-mediated asparaginase resistance in the coculture assays. To discriminate whether the major source of IGFBP7 in the coculture assays was ALL or stromal cells, coculture experiments were performed with the IGFBP7 knockdown cell lines, and the levels of extracellular IGFBP7 in the conditioned culture media were measured by ELISA. As shown in Figure 5a and Supplementary Figure  7 , extracellular IGFBP7 levels, after 24 h of culture, were more severely affected by IGFBP7 knockdown in ALL cells (REH and RS4;11) than in the MSCs. Compatible results were obtained when analyzing the conditioned culture media of primary ALL cells on BMSC layers. As shown in Figure 5b , there was a significant correlation between intracellular (median fluorescence intensity of ALL labeled cells) and extracellular IGFBP7 levels. These results seem to indicate that ALL cells, when in high numbers, contribute substantially to IGFBP7 levels in the conditioned media from in-vitro coculture experiments. Results would be different if fewer ALL cells were added to the assays. Stromal cells are estimated to represent 2--3% of the total mononuclear cells of the BM. 42 In the experiments shown in Figure 4 , stromal cells were used at a proportion of 3-4%: 100 000 REH/RS4;11 cells were seeded onto B3000 MSCs, and 200 000 primary ALL were seeded onto B8000 BMSCs.
Since the leukemic BM is fully dominated by leukemia cells, it is likely that IGFBP7 levels in the leukemic BM would correlate with IGFBP7 expression by ALL cells. Diagnostic BM plasma samples (n ¼ 90) from children with ALL demonstrated significantly higher levels of IGFBP7 than that of control (n ¼ 16) subjects (median 49.33 ng/ml vs 30.9 ng/ml, P ¼ 0.0001; Figure 5c) . The median IGFBP7 level in adult serum was reported to be in the range of 21 --35 ng/ml. 43 Importantly, the leukemic BM plasma levels of IGFBP7 correlated with IGFBP7 transcript levels in the corresponding ALL samples (n ¼ 42), corrected according to blasts concentration in BM (Figure 5d ). rIGFBP7 stimulates the expression of the ASNS gene in BMSCs Recently, BM mesenchymal cells were shown to express high levels of ASNS and to secrete sufficient amounts of asparagine into the culture medium to protect primary ALL cells from asparaginase cytotoxicity. 22 We, therefore, investigated if the addition of rIGFBP7 to the culture medium would stimulate the expression of ASNS by BMSCs. As shown in Figure 6a , rIGFBP7 induced a clear increase in ASNS expression in a time-dependent manner, being maximal (twofold) after 6 h. IGFBP7 is known to act through the binding to different IGFs and chemokines. 34, 35 Some of these soluble factors are known to be secreted by BMSCs, 44 --46 thus mediating the observed effects of rIGFBP7 addition with no ligand, in serum-free medium.
When rIGFBP7 was added to the culture in conjunction with insulin, an additive ASNS upregulation was observed compared with the effect of each factor separately (Figure 6b ). Similar effects were observed when IGF1 or IGF2 were substituted for insulin (Supplementary Figure 8) .
To address whether higher levels of ASNS expression by BMSCs translated into higher levels of asparagine availability to ALL cells, we measured amino-acid levels in the culture supernatants collected from BMSCs after 24 and 48 h of stimulation with rIGFBP7 and/or one of its ligands. Treatment of BMSCs with rIGFBP7 resulted in significantly higher levels of asparagine in comparison with unstimulated cells. Moreover, a strong additive effect on asparagine abundance was observed when rIGFBP7 was used in conjunction with insulin, IGF1 or IGF2 (Figure 6c ; Supplementary Table 2) .
Prognostic significance of IGFBP7 expression levels The expression levels of IGFBP7 were quantified by RQ-PCR in a series of 181 diagnostic samples from ALL patients treated A complete list of patient features and IGFBP7 expression is given in Table 1 . IGFBP7 mRNA expression levels were lower in children with T-cell immunophenotype (n ¼ 20; P ¼ 0.04). Associations between IGFBP7 expression levels and some clinical and ; scr, cells transduced with sh.Scrambled. Asparaginase was used at 2, 0.001 and 3 IU/ml for REH, RS4;11 and 697, respectively. When indicated, rIGFBP7 was used at 100 ng/ml. After 48 h, cells were labeled with Annexin V and PI and the absolute number of viable cells was recorded by FACS in conjunction with fluorescent beads added for normalization. Representative dot plots are shown in Supplementary  Figure 4 . Values represent the absolute number of viable cells for each cell combination, with asparaginase, relative to the same cell combination without asparaginase. Data shown correspond to mean ± s.e.m. Statistical analysis was done by two-way ANOVA and Bonferroni post-tests for comparisons between scr þ scr vs all other cell combinations (*Po0.05; **Po0.01; ***Po0.001).
biological variables at diagnosis were investigated in the subgroup of B-precursor ALL. Leukemic blasts from patients with o1 or X10-year old (n ¼ 40; P ¼ 0.008) or lacking CD10 expression (n ¼ 7; P ¼ 0.007) had higher IGFBP7 mRNA expression levels. To investigate the potential influence of IGFBP7 expression on chemotherapy resistance, LFS was analyzed in a Cox regression model using IGFBP7 expression (IGFBP7/ABL) as a continuous logtransformed variable, so avoiding any arbitrary cutoff point. When all precursor B-cell ALL patients were included in the analysis, patients with higher IGFBP7 expression (log value) had a tendency to a lower probability of LFS (P ¼ 0.06). The Ph chromosome is an independent unfavorable prognostic factor. Accordingly, three out of the five Ph( þ ) patients of B-phenotype relapsed. All Ph( þ ) patients had IGFBP7 expression below the median, thus introducing a potential confounder in the analysis of the clinical impact of IGFBP7 expression. When Ph( þ ) patients were excluded from the analysis, patients with higher IGFBP7 expression levels had significantly lower LFS (hazard ratio for unit increase in ln IGFBP7 1.766, 95% confidence interval 1.208 --2.582, P ¼ 0.003). Accordingly, the subgroup of patients that had refractory disease or postremission relapse was significantly associated with higher IGFBP7 expression levels (n ¼ 10; P ¼ 0.002; Table 1 ). To illustrate these findings, patients were divided into quartiles according to IGFBP7 expression and Kaplan --Meier survival curves were compared by the log-rank test for trend (Figure 7) . In multivariate analysis, only risk group and IGFBP7 expression were significantly and independently associated with LFS (P ¼ 0.009 and P ¼ 0.05, respectively). The limited number of patients with ELISA-measured IGFBP7 levels in diagnostic BM plasma precluded any conclusive analysis regarding its association with other clinicobiological variables (data not shown). Together, these data suggest that IGFBP7 expression may contribute to increased resistance to polychemotherapy in Ph(À) precursor B-cell ALL, even though additional studies in a larger cohort of patients are needed to fully substantiate this finding. Table 1) were cultured onto MSC stromal layers and exposed to asparaginase (0.9 IU/ml) or asparaginase in combinations with rIGFBP7 (100 ng/ml) and/or insulin (500 ng/ml) in AIM-V serum-free medium. 
DISCUSSION
Previous studies have shown that leukemia cells establish privileged interactions with BMSCs, resulting in the protection of tumor cells from the cytotoxic effects of chemotherapy. 36 The recent definition of a series of genes possibly associated with ALL resistance/sensitivity to chemotherapy 24 prompted us to investigate whether some of these genes could be involved in stromal cell regulation of ALL drug resistance. In an initial screening of five genes associated with asparaginase-resistant ALL, 24 we found that IGFBP7 transcript levels were significantly upregulated in primary ALL cells and stromal-independent ALL cell lines upon coculture with BM stromal layers. Similar results were found when IGFBP7 Table 1 , which also includes data obtained with IGF2 (200 ng/ml) ± IGFBP7. levels were measured at the protein level both within ALL cells and in conditioned culture media. The ALL-derived IGFBP7 was shown to exert a positive impact on the growth of ALL and stromal cells, in an autocrine and paracrine manner, respectively. More importantly, both ALL-derived IGFBP7 and addition of rIGFBP7 protein to coculture experiments counteracted the effect of asparaginase on ALL survival. IGFBP7 (mac25/TAF/AGM), renamed as IGFBP-rP1, is a secreted 30-kDa protein that belongs to a subfamily of low affinity IGFBPs, shown to have different roles in different cellular (tumor) contexts. IGFBP7 was initially described as an enhancer of the mitogenic activities of IGFs and insulin in fibroblastic cells. Later on, IGFBP7 has also been ascribed properties of both tumor suppressor and enhancer of cell proliferation. 47, 48 Recent data suggest a stimulatory effect of IGFBP7 in the adhesion, migration and proliferation of acute myeloid leukemia. 49 Conversely, IGFBP7 was found to induce senescence in T-ALL cell lines. 50 The later results were obtained using IGFBP7 at concentrations above 5 mg/ml. At these high IGFBP7 concentrations, we also found an inhibitory effect on the proliferation of B-lineage ALL cell lines (data not shown).
IGFBP products function in IGF-dependent or IGF-independent ways to regulate normal and neoplastic cell growth. 35, 51, 52 We found that ALL resistance to asparaginase was higher when rIGFBP7 was added in conjunction with insulin. Asparaginase exerts its effects by depleting asparagine (and glutamine) from the serum. Since ALL cells have low intracellular ASNS activity, they mostly depend on an extracellular supply of this amino acid and are therefore sensitive to asparagine starvation. Recently, Iwamoto et al. 22 demonstrated that ASNS expression by BM mesenchymal cells was directly related to increased asparagine secretion into the culture medium and functioned to protect cocultured ALL cells from asparaginase cytotoxicity. Our data extend these findings by suggesting one possible mechanism of bidirectional signaling between ALL cells and BMSCs, where BMSCs stimulate ALL cell expression of IGFBP7, a secreted factor that, in an insulin/ IGF-dependent manner, enhances ASNS expression and asparagine secretion by BMSCs and thereby counteracts the cytotoxic effects of asparaginase. Accordingly, the ectopic expression of IGF-1 or IGF-2 in MCF7 breast cancer cells was reported to upregulate several genes involved in amino-acid transport and biosynthesis, including ASNS. 53 Although IGFBP7 stimulation of asparagine production by BMSCs is one likely reason for the observed protection of ALL cells, many other BM stromal factors could also have been regulated by the addition of IGFBP7 and could account for its effects.
IGFs and insulin increase amino-acid uptake and stimulate protein synthesis in many different cell types. Moreover, IGFs are well-known survival factors, which protect cells from different apoptotic stimuli, including corticoid treatment. 19,54 --56 Evidence exists that ALL cells, both primary cells and cell lines, respond to IGFs or insulin stimulation. 36 --41 It is, therefore, conceivable that IGFBP7, in conjunction with one of its ligands, may have exerted a direct protective effect on ALL cells, either by stimulating asparagine/glutamine synthesis or by inhibiting apoptosis. In preliminary experiments, only a few of our primary ALL samples showed increased resistance to asparaginase when cultured alone in medium with rIGFBP7 plus insulin (three out of nine samples assayed; data not shown). However, the results should be interpreted with caution, because primary ALL cells have a strong tendency to die when cultured in medium alone; 12 therefore, a direct effect of IGFBP7:insulin on ALL resistance to asparaginase may have been underestimated. In the case of ALL cell lines, which survive equally well with and without BMSCs, the addition of IGFBP7 plus insulin resulted in increased resistance against asparaginase even in the absence of stromal cells.
Cultured BMSCs were found to express IGFBP7 to levels higher (median of 10.15) than most diagnostic samples of ALL cells (median of 1.43), though this may not represent their actual behavior in vivo. Therefore, ASNS expression by BMSCs is also subjected to autocrine, in addition to paracrine and endocrine, IGFBP7 regulation. In any case, at a proportion of B30:1, ALL cells were found to contribute substantially to IGFBP7 levels in the conditioned coculture medium. Moreover, IGFBP7 protein levels in diagnostic BM plasma from patients correlated with the levels of IGFBP7 mRNA in ALL cells, corrected according to blasts concentration in BM, thus suggesting a significant role for leukemic blasts on the levels of this molecule.
In a retrospective analysis of a group of 181 pediatric ALL samples treated in a single institution, higher IGFBP7 levels (mRNA) were associated with worse LFS of precursor B-cell ALL patients. Although we present evidence of a possible mechanism that may explain IGFBP7 participation in ALL resistance to asparaginase, the observed impact of IGFBP7 on LFS seems to suggest a role for this protein, and the IGF/insulin axis, in ALL resistance to other chemotherapeutic agents. Prospective studies in a larger cohort of patients and including the evaluation of IGF and insulin levels are awaited.
In conclusion, our data support a model in which IGFBP7 is involved in the cross talk between leukemic cells and BMSCs, which may be important in protecting ALL blasts from asparaginase. Gene transcript values were normalized with respect to the number of ABL transcripts. Six patients that had induction deaths and five positive for BCR-ABL were excluded from analysis. The remaining patients were divided into quartiles according to IGFBP7 expression levels (first to third quartile had 37 patients each; fourth quartile had 36 patients). LFS denotes period of time from remission date to any relapse. Failure to enter remission due to refractory disease was considered an event at time zero. Patients who died in remission as well as those still alive with no event were censored at last follow-up. Curves were analyzed with the log-rank test for trend.
